Genetic structure and regulation of HIV.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Genetic structure and regulation of HIV.

Harvard AIDS Inst Ser; 1:1-537 1991. Unique Identifier : AIDSLINE ICDB/93686276
Anonymous; No affiliation given

Abstract: The most profound theme to emerge from studies of the human retroviruses is that regulation of gene expression can be achieved via binding of regulatory proteins to specific regions of the viral RNA. Two of the essential regulatory proteins of HIV-1, the transactivator gene (tat) and the regulator of virion protein-expression gene (rev), must bind to specific regions of viral RNA to function. The essential human T-cell leukemia virus-1 (HTLV-1) regulatory protein, the regulator of virion protein expression (rex), also binds to a specific viral RNA sequence. These discoveries necessarily shift the emphasis of gene regulation studies from examination of events that precede transcription initiation to regulatory events that follow initiation and depend on recognition of RNA sequences already transcribed. This volume provides a framework for understanding studies of the HIV-1 tat and rev; the chapters derive from a workshop sponsored by the Harvard AIDS Institute held at Babson College, Wellesley, Massachusetts, November 5-7, 1990. Major topics, most of which are covered in more than one chapter, are HIV-1 transactivator, the HIV-1 regulator of virion protein expression, the HIV long-terminal repeat, other HIV regulatory genes, retroviral envelope glycoprotein genes and infection of dendritic cells.

Keywords: Dendritic Cells/MICROBIOLOGY *Gene Expression Regulation Gene Products, rev Gene Products, rex Gene Products, tat *Genes, Viral HIV Long Terminal Repeat HIV-1/*GENETICS/ISOLATION & PURIF RNA, Viral/GENETICS Trans-Activators Transcription, Genetic Viral Envelope Proteins/GENETICS MONOGRAPH
930228
M9320884

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .